Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences Inc.

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Caribou Biosciences, with a price target of $...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRBU	$1.79	-3.76%	1.14M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRBU	$1.79	-3.8%	1.14M
3
4
5
6

CRBU

CRBU

No Data Available

Get Caribou Biosciences Inc. Data in Excel

Get Caribou Biosciences Inc. Data in Excel